BLUFIn a drug trial of patients in the early stages of Alzheimer's, an experimental drug 'Lecanemab' slowed the progress of the disease by 27%.
This article by Deena Beasley, Julie Steenhuysen and Rocky Swift, writing for Reuters, makes the following points:
- To date, every drug tried to combat Alzheimers has failed.
- The brain-wasting disease affects about 55 million people globally.
- The new drug, Lecanemab, slowed the progress of the disease by 27%.
- The downside is that the drug is very expensive.
References from the Web:
- SEP 2022 Alzheimer’s Progression Slowed by Drug in Major Trial—Bloomberg
- SEP 2022 Biogen Stock Jumps 35% After Promising Results For New Alzheimer’s Drug—Forbes